Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 142Leukemia 41Leukemia, Myeloid, Chronic-Phase 35Blast Crisis 17Philadelphia Chromosome 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Myeloid, Accelerated Phase 10Leukemia, Myeloid 9Primary Myelofibrosis 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Myeloid, Acute 7Polycythemia Vera 6Myeloproliferative Disorders 6Hypereosinophilic Syndrome 5Hematologic Neoplasms 5Hematologic Diseases 5Bone Marrow Diseases 5Multiple Myeloma 4Gastrointestinal Stromal Tumors 4Thrombocythemia, Essential 3Myelodysplastic Syndromes 3Mastocytosis 3Leukemia, Lymphocytic, Chronic, B-Cell 3Bronchiolitis Obliterans Syndrome 3Recurrence 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Neoplasms by Histologic Type 2Neoplasms 2Neoplasm, Residual 2Mastocytosis, Systemic 2

Interventions

ripretinib 1Imatinib Mesylate 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mast Cell Activation Disorders × Imatinib Mesylate × Myeloid × Clear all
NCT01297777 2016-08-29

Imatinib in KIT-negative Systemic Mastocytosis

Hospital Virgen de la Salud

Phase 4 Completed
10 enrolled
Myeloid

Mast Cell Activation Disorders, Mastocytosis, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡